Iwona Skorulska

Iwona Skorulska

Auto-generated profile, based on publicly available information

Iwona Skorulska

University Clinical Hospital in Bialystok

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WGWeronika Barbara Grywińska
Weronika Barbara Grywińska
AOAleksandra Okońska
Aleksandra Okońska
JKJulia Kozakiewicz
Julia Kozakiewicz
KKKamil Kościelecki
Kamil Kościelecki
AKAgnieszka Kalisz
Agnieszka Kalisz
AGAleksandra Głowacka
Aleksandra Głowacka
Introduction: Eating disorders (EDs) are complex mental health conditions with significant treatment barriers, including stigma and limited access to care. Virtual reality (VR) offers a novel approach by providing immersive, controlled environments for addressing body image concerns and maladaptive eating behaviours. This review explores VR’s potential in ED treatment based on recent research. Methods: A literature review was conducted using PubMed, Google Scholar, and Web of Science, focusing on studies from the past five years that examined VR as a treatment tool. Clinical outcomes, intervention types, and methodologies were analysed. Summary of Findings: VR has shown promise in reducing body dissatisfaction, fear of weight gain, and binge eating behaviours. Studies using personalized avatars, attentional bias training, and exposure therapy demonstrated improvements in body image perception, anxiety reduction, and coping skills. VR-enhanced cognitive behavioural therapy (VR-CBT) was particularly effective for bulimia nervosa and binge eating disorder. Conclusions: VR is an effective, accessible tool for ED treatment, offering safe and engaging therapeutic experiences. While promising, further research is needed to refine treatment protocols and enhance personalization. As technology advances, VR has the potential to bridge treatment gaps and improve ED recovery outcomes.

11 May 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
PDPatrycja Długozima
Patrycja Długozima
KMKlaudia Mączewska
Klaudia Mączewska
DHDominika Hakało
Dominika Hakało
JKJulia Kozakiewicz
Julia Kozakiewicz
KKKamil Kościelecki
Kamil Kościelecki
AGAleksandra Głowacka
Aleksandra Głowacka
Introduction: Glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors in adults, known for its rapid progression and poor prognosis. Despite advancements in surgical resection, radiotherapy, and chemotherapy, the median survival for GBM patients remains limited. In recent years, Tumor Treating Fields (TTFields), commercially known as Optune, have emerged as an innovative, non-invasive therapeutic approach. TTFields utilize alternating electric fields to interfere with the mitotic processes of cancer cells, thereby inhibiting tumor growth. This paper aims to provide an in-depth review of the current understanding of TTFields therapy, assess its clinical efficacy, and explore future directions in GBM management. Materials and methods: A systematic literature review was conducted, focusing on peer-reviewed articles published between 2017 and 2025. The search was performed using databases such as PubMed, JAMA, Lancet Oncology, Neuro-Oncology etc. Keywords included “glioblastoma,” “Tumor Treating Fields,” “Optune,” “clinical trials,” and “survival outcomes”. Summary: The integration of TTFields therapy into the standard GBM treatment regimen represents a significant advancement in neuro-oncology. Clinical evidence indicates that TTFields, particularly in combination with temozolomide, can extend survival and delay disease progression in GBM patients. Conclusions: TTFields therapy has emerged as a promising adjunctive treatment for glioblastoma, offering new hope for patients facing this highly aggressive disease. While current data support its efficacy and safety, further large-scale studies are needed to refine treatment protocols, identify predictive biomarkers, and assess long-term benefits. As research advances, TTFields may become an integral part of multimodal glioblastoma therapy, potentially improving both survival rates and quality of life for patients.

7 April 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
ISIwona Skorulska
Iwona Skorulska
PGPaulina Grzeszczuk
Paulina Grzeszczuk
AGAleksandra Głowacka
Aleksandra Głowacka
JKJulia Kozakiewicz
Julia Kozakiewicz
AOAleksandra Okońska
Aleksandra Okońska
AKAgnieszka Kalisz
Agnieszka Kalisz
Introduction: This review paper aims to systematize the current knowledge about Mondor's disease, its etiology and epidemiology, diagnostic methods, differential diagnosis, and therapeutic approaches. Furthermore, it examines the prognosis and potential complications based on a comprehensive review of the available literature. Materials and methods: A review of selected literature in the PubMed database was conducted, using the following keywords: ,,Mondor’s disease”, ,,vein thrombosis”, ,,superficial thrombophlebitis”. Summary: Mondor’s disease is a rare, self-limiting superficial thrombophlebitis, primarily affecting the anterior chest wall but also documented in the abdomen, axilla, groin, and penis. Its etiology remains unclear, though mechanical stress, inflammation, and hypercoagulability are implicated. It predominantly affects middle-aged women. Though benign, its clinical presentation may mimic malignancies, causing significant distress.Diagnosis is primarily clinical, based on a palpable, tender, cord-like structure without systemic symptoms. Imaging, particularly ultrasonography, is warranted when malignancy is suspected. Mammography or Magnetic Resonance Imaging may be used to exclude neoplastic conditions.Management is conservative, focusing on NSAIDs, topical therapies, and activity modification. Anticoagulation is generally unnecessary but may be considered in extensive thrombosis. Surgical intervention is rare. Prognosis is favorable, with spontaneous resolution within weeks, though secondary cases require treatment of the underlying condition. Conclusions: Healthcare providers must recognize Mondor’s disease to ensure accurate diagnosis and effective management. While conservative treatment remains the standard, further research into its pathophysiology may refine diagnostic and therapeutic strategies. In recurrent or secondary cases, vigilance for thrombotic disorders or malignancies is essential for comprehensive patient care.

7 April 2025 in Quality in Sport
Verified
Journal Article
Open access
KKKamil Kościelecki
Kamil Kościelecki
AKAgnieszka Kalisz
Agnieszka Kalisz
AOAleksandra Okońska
Aleksandra Okońska
JKJulia Kozakiewicz
Julia Kozakiewicz
ISIwona Skorulska
Iwona Skorulska
KMKlaudia Mączewska
Klaudia Mączewska
Introduction: This review paper aims to emphasize how Alpha-1-antitrypsin deficiency is how can lead to serious disease states, indicating the pathophysiology, symptoms, diagnostic possibilities, therapeutic methods and proving that early diagnostics for this deficiency can protect the patient from its serious consequences Materials and methods: A review of chosen literature in the PubMed database was conducted, using the following keywords: „Alpha-1-antitrypsin deficiency”, „Alpha-1-antitrypsin” Summary: Alpha-1-antitrypsin deficiency is a relatively common condition that is often overlooked in diagnostic evaluations. It can lead to serious health complications, substantially reduce quality of life, and even shorten a patient's lifespan. Early diagnosis is essential because it allows for the adoption of healthier lifestyle habits and more consistent health monitoring, which can help mitigate the condition’s long-term consequences. Conclusions: Symptoms of alpha-1 antitrypsin deficiency are quite prevalent and can affect individuals across all age groups—from infants and children to adults and the elderly. This deficiency may lead to serious complications, including COPD, emphysema, asthma, liver cirrhosis, hepatocellular carcinoma (HCC). A deep understanding of its pathophysiology has enabled the development of improved diagnostic techniques and novel treatment strategies. For instance, in young adults with COPD and children exhibiting signs of liver disease, it is advisable to measure alpha-1 antitrypsin levels or perform genotyping. In cases where a significant deficiency is detected, initiating replacement therapy and closely monitoring the patient's health is crucial.

3 April 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
PGPaulina Grzeszczuk
Paulina Grzeszczuk
AGAleksandra Głowacka
Aleksandra Głowacka
ISIwona Skorulska
Iwona Skorulska
WGWeronika Barbara Grywińska
Weronika Barbara Grywińska
AKAgnieszka Kalisz
Agnieszka Kalisz
KKKamil Kościelecki
Kamil Kościelecki
Introduction: This review paper aims to explore the current state of knowledge regarding the underlying mechanisms of Schnitzler syndrome, its clinical manifestations, the diagnostic challenges, and to analyze current treatment approaches, along with potential complications related to the disease. Materials and Methods: A comprehensive review of the literature was conducted using the PubMed and Google Scholar databases using the following keywords: "Schnitzler syndrome", "Schnitzler-like syndrome", "NETosis", "urticaria", "fever", "monoclonal gammopathy", "neutrophilic dermatosis", "anakinra", "treatment". Summary: Schnitzler syndrome is a rare autoinflammatory disease that typically affects adults and presents with symptoms such as recurrent urticaria, fever, monoclonal gammopathy, and musculoskeletal pain. The exact cause is still not fully understood, but IL-1 antagonists have shown promising results, indicating IL-1's role in the disease's development. Despite the established diagnostic criteria, the disease still presents significant diagnostic challenges, often leading to delays in recognition or even underdiagnosis. Schnitzler syndrome, particularly if left untreated, can lead to complications such as the development of lymphoproliferative disorders, most commonly Waldenström's macroglobulinemia or, in rare cases, AA amyloidosis. Conclusions: This review emphasizes the importance of a thorough examination, as its symptoms often resemble those of other diseases, which can lead to misdiagnosis. Due to the complexity of the clinical presentation, effective collaboration among dermatologists, rheumatologists and immunologists is essential. Ongoing research is crucial to better understand the disease’s pathogenesis and to develop more effective and personalized treatment strategies. Keywords: Schnitzler syndrome, neutrophilic urticarial dermatosis, monoclonal gammopathy

27 November 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MJMagdalena Jabłonowska
Magdalena Jabłonowska
PGPaulina Grzeszczuk
Paulina Grzeszczuk
ISIwona Skorulska
Iwona Skorulska
Introduction: This review aims to provide a comprehensive examination of Tangier disease, focusing on its clinical manifestations, pathophysiology, and diagnostic methods. The article also delves into the available management strategies, the challenges in treating this rare condition, and the ongoing research into potential therapeutic interventions. Materials and Methods: A comprehensive review of the literature was conducted using the PubMed and Google Scholar databases with the following keywords: "Tangier disease", "HDL deficiency", "ABCA1", "neuropathy", "high-density lipoprotein ", "HDL", "apoA-I", "CETP", "atherosclerosis", "splenomegaly". Summary: Tangier disease is a rare autosomal recessive genetic disorder caused by mutations in the ABCA1 gene, which impairs cholesterol transport and results in low levels of HDL. This leads to the accumulation of cholesterol esters in various tissues, including the tonsils, spleen, lymph nodes, and nerves. The disease is characterized by orange-colored, enlarged tonsils, splenomegaly, peripheral neuropathy, and a heightened risk for atherosclerotic cardiovascular disease. Diagnosis is confirmed through low HDL and apoA-I levels, along with genetic testing for ABCA1 mutations. While no cure exists, treatment focuses on symptom management, controlling cardiovascular risks, and improving HDL function through lifestyle and dietary changes. Conclusions: Tangier disease, a rare genetic disorder caused by mutations in the ABCA1 gene, leads to severe lipid imbalances and various systemic complications. Although there is no cure, managing symptoms, controlling cardiovascular risks, and adopting lifestyle changes are essential for improving outcomes. Ongoing research into gene therapies and new treatments offers hope for future breakthroughs.